measles, mumps, rubella, varicella vaccine
Trade name: ProQuad
Vaccineapproved
Approved
Sep 6, 2005
Clinical trial activity
18 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
15
Phase 3
12
Phase 4
3
Earliest trial started Aug 1, 2000 (NCT00985166)
Timeline
Indications
Studied for
- Bacterial Infections · Phase 3
- Chickenpox · Phase 4
- Diphtheria · Phase 3
- Haemophilus Infections · Phase 3
- Heart Diseases · Phase 1/Phase 2
- Hepatitis A · Phase 4
- Hepatitis A virus · Phase 4
- Hepatitis B · Phase 3
- Liver Failure, Acute · Phase 1/Phase 2
- Measles · Phase 4
- Meningitis, Meningococcal · Phase 3
- Mumps · Phase 4
- Poliomyelitis · Phase 3
- Renal Insufficiency, Chronic · Phase 1/Phase 2
- Rubella · Phase 4
- Tetanus · Phase 3
- Virus Diseases · Phase 3
- Whooping Cough · Phase 3
Mechanism of action
- Variola virusImmunity, active
Variola virus immunity, active
- Rubella virusImmunity, active
Rubella virus immunity, active
- Measles virusImmunity, active
Measles virus immunity, active
Approval history
- approvedSep 6, 2005
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- measles, mumps, rubella and chickenpox
- measles, mumps, rubella and varicella
- measles-mumps-rubella-varicella vaccine
- measles, mumps, rubella, varicella vaccine
- mmrv vaccine
- proquad
- proquad
- pro-quad
- virus, live attenuated, measles, virus, live attenuated, mumps, virus, live attenuated, rubella, virus, live attenuated, varicella
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02687763 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2015 | Medical University of South Carolina, University of South Carolina |
| NCT01341639 | Phase 3 | May 1, 2011 | Merck, Sanofi-Aventis |
| NCT00839917 | Phase 3 | Feb 1, 2008 | Merck |
| NCT00566527 | Phase 3 | Nov 1, 2007 | Merck, Sanofi-Aventis |
| NCT00578175 | Phase 2 | Nov 1, 2007 | GlaxoSmithKline |
| NCT00560755 | Phase 3 | Oct 1, 2007 | Merck, Sanofi-Aventis |
| NCT00483574 | Phase 3 | May 1, 2007 | Sanofi |
| NCT00326183 | Phase 4 | Mar 1, 2007 | Merck |
| NCT00432042 | Phase 3 | Jan 1, 2007 | Merck, Sanofi-Aventis |
| NCT00422292 | Phase 3 | Dec 1, 2006 | Sanofi |
| NCT00402831 | Phase 3 | Oct 1, 2006 | Merck, Sanofi-Aventis |
| NCT00312858 | Phase 4 | Apr 1, 2006 | Merck |
| NCT00109343 | Phase 3 | Mar 1, 2006 | Merck |
| NCT00127010 | Phase 3 | Nov 1, 2005 | GlaxoSmithKline |
| NCT00258726 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2005 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00127023 | Phase 3 | May 1, 2005 | GlaxoSmithKline |
| NCT00126997 | Phase 4 | May 1, 2005 | GlaxoSmithKline |
| NCT00985166 | Phase 3 | Aug 1, 2000 | Merck |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 10 | 9 | 2 | 2000 |
| Sanofi-Aventis | For profit | 5 | 1 | 1 | 2006 |
| GlaxoSmithKline | For profit | 4 | 4 | 3 | 2005 |
| Sanofi | For profit | 2 | 2 | 1 | 2006 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 2015 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2005 |
| University of South Carolina | Academic/Hospital | 1 | 1 | 1 | 2015 |
7 organizations
Page 1 / 1